Characteristic | Â | Adipo-IR | P Value | ||||
---|---|---|---|---|---|---|---|
Total | Q1(N = 447)a | Q2(N = 440) | Q3(N = 447) | Q4(N = 441) | Q5(N = 447) | Â | |
Sex (male), n (%) | 1533 (69.0) | 343 (76.7) | 326 (74.1) | 308 (68.9) | 282 (63.9) | 274 (61.3) | < 0.001 |
Age, y, mean (SD) | 62.5 ± 11.5 | 64.3 ± 10.8 | 63.4 ± 10.5 | 63.0 ± 11.5 | 61.2 ± 11.9 | 60.6 ± 12.5 | < 0.001 |
Body mass index, kg/m2, mean (SD) | 24.5 ± 3.3 | 23.4 ± 2.8 | 24.1 ± 3.1 | 24.4 ± 3.1 | 24.9 ± 3.2 | 25.9 ± 3.5 | < 0.001 |
Laboratory tests at admission | Â | Â | Â | Â | Â | Â | Â |
 TG, mmol/L, mean (SD) | 1.4 ± 0.8 | 1.2 ± 0.5 | 1.3 ± 0.6 | 1.4 ± 0.6 | 1.6 ± 0.8 | 1.8 ± 1.2 | < 0.001 |
  TC, mmol/L, mean (SD) | 4.0 ± 1.0 | 3.8 ± 0.9 | 3.9 ± 0.9 | 4.0 ± 1.0 | 4.1 ± 1.1 | 4.3 ± 1.1 | < 0.001 |
  HDL-C, mmol/L, mean (SD) | 1.0 ± 0.3 | 1.1 ± 0.3 | 1.0 ± 0.2 | 1.0 ± 0.3 | 1.0 ± 0.3 | 1.0 ± 0.3 | < 0.001 |
  LDL-C, mmol/L, mean (SD) | 2.4 ± 0.9 | 2.2 ± 0.8 | 2.3 ± 0.8 | 2.4 ± 0.9 | 2.4 ± 0.9 | 2.6 ± 1.1 | < 0.001 |
Medical history, n (%) | Â | Â | Â | Â | Â | Â | Â |
  Prior stroke | 501 (22.5) | 97 (21.7) | 93 (21.1) | 117 (26.2) | 98 (22.2) | 96 (21.5) | 0.36 |
  Coronary heart disease | 193 (8.7) | 33 (7.4) | 34 (7.7) | 44 (9.8) | 37 (8.4) | 45 (10.1) | 0.50 |
  Atrial fibrillation | 171 (7.7) | 45 (10.1) | 34 (7.7) | 35 (7.8) | 27 (6.1) | 30 (6.7) | 0.22 |
  Hypertension | 1306 (58.8) | 243 (54.4) | 236 (53.6) | 261 (58.4) | 264 (59.9) | 302 (67.6) | < 0.001 |
  Dyslipidemia | 106 (4.8) | 11 (2.5) | 11 (2.5) | 29 (6.5) | 18 (4.1) | 37 (8.3) | < 0.001 |
Current smoking, n (%) | 727 (32.7) | 179 (40.0) | 155 (35.2) | 144 (32.2) | 133 (30.2) | 116 (26.0) | < 0.001 |
Regular drinking, n (%) | 318 (14.3) | 71 (15.9) | 75 (17.0) | 61 (13.6) | 58 (13.2) | 53 (11.9) | 0.17 |
Pre-stroke mRS 3–5, n (%) | 94 (4.2) | 18 (4.0) | 14 (3.2) | 17 (3.8) | 17 (3.9) | 28 (6.3) | 0.19 |
Medication history | Â | Â | Â | Â | Â | Â | Â |
  Antihypertensive agents | 934 (42.0) | 161 (36.0) | 174 (39.5) | 186 (41.6) | 201 (45.6) | 212 (47.4) | 0.004 |
  Lipid-regulating agents | 227 (10.2) | 36 (8.1) | 36 (8.2) | 55 (12.3) | 46 (10.4) | 54 (12.1) | 0.09 |
  Anticoagulants | 17 (0.8) | 3 (0.7) | 2 (0.5) | 7 (1.6) | 1 (0.20 | 4 (0.9) | 0.19 |
  Antiplatelet agents | 364 (16.4) | 57 (12.8) | 75 (17.0) | 80 (17.9) | 69 (15.6) | 83 (18.6) | 0.14 |
NIHSS at admission, median (IQR) | 3.0 (2.0–6.0) | 3.0 (2.0–6.0) | 4.0 (2.0–6.0) | 3.0 (2.0–6.0) | 3.0 (1.0–6.0) | 4.0 (2.0–6.0) | 0.28 |
Stroke etiology, n (%) | Â | Â | Â | Â | Â | Â | 0.01 |
  Large-artery atherosclerosis | 567 (25.5) | 99 (22.1) | 120 (27.3) | 118 (26.4) | 126 (28.6) | 104 (23.3) |  |
  Cardioembolism | 148 (6.7) | 43 (9.6) | 34 (7.7) | 29 (6.5) | 19 (4.3) | 23 (5.1) |  |
  Small-artery occlusion | 514 (23.1) | 115 (25.7) | 85 (19.3) | 91 (20.4) | 109 (24.7) | 114 (25.5) |  |
  Others | 993 (44.7) | 190 (42.5) | 201 (45.7) | 209 (46.8) | 187 (42.4) | 206 (46.1) |  |
Urinary infection, n (%) | 22 (1.0) | 5 (1.1) | 7 (1.6) | 7 (1.6) | 2 (0.5) | 1 (0.2) | 0.13 |
Pulmonary infection, n (%) | 102 (4.6) | 18 (4.0) | 17 (3.9) | 21 (4.7) | 27 (6.1) | 19 (4.3) | 0.50 |
Medicines during hospitalization, n (%) | Â | Â | Â | Â | Â | Â | Â |
  Antiplatelet agents | 2149 (96.7) | 435 (97.3) | 420 (95.5) | 434 (97.1) | 430 (97.5) | 430 (96.2) | 0.41 |
  Antihypertensive agents | 958 (43.1) | 156 (34.9) | 155 (35.2) | 191 (42.7) | 233 (52.8) | 223 (49.9) | < 0.001 |
  Lipid-lowering agents | 2138 (96.2) | 428 (95.7) | 423 (96.1) | 427 (95.5) | 430 (97.5) | 430 (96.2) | 0.23 |
  Warfarin | 54 (2.4) | 9 (2.0) | 13 (3.0) | 10 (2.2) | 9 (2.0) | 13 (2.9) | 0.81 |
  Intravenous alteplase | 231 (10.4) | 30 (6.7) | 53 (12.0) | 53 (11.9) | 56 (12.7) | 39 (8.7) | 0.01 |
Medicine use during 1-year follow-up | Â | Â | Â | Â | Â | Â | Â |
  Antihypertensive agents | 1068 (48.1) | 191 (42.7) | 185 (42.0) | 198 (44.3) | 255 (57.8) | 239 (53.5) | < 0.001 |
  Lipid-regulating agents | 1607 (72.3) | 338 (75.6) | 321 (73.0) | 309 (69.1) | 325 (73.7) | 314 (70.2) | 0.19 |
  Anticoagulants | 67 (3.0) | 13 (2.9) | 15 (3.4) | 12 (2.7) | 12 (2.7) | 15 (3.4) | 0.51 |
  Antiplatelet agents | 1761 (79.3) | 370 (82.8) | 344 (78.2) | 352 (78.7) | 352 (79.8) | 352 (79.8) | 0.14 |